Intelligence Feed event · Capital · 2026-09-20

    Electra Therapeutics sets terms for $347M Nasdaq IPO under ticker ETRA

    Question

    Electra Therapeutics sets terms for $347M Nasdaq IPO under ticker ETRA

    Direct answer

    Electra Therapeutics established pricing parameters for its upcoming Nasdaq listing, planning to raise up to $347 million across 21.7 million shares at $14-$16 each. The capital injection will fund the clinical development and pivotal registration trials of ipsoprubart, serving as a gauge for institutional ECM demand in clinical-stage biotherapeutics.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-20
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Electra Therapeutics sets terms for $347M Nasdaq IPO under ticker ETRA”, revision 1, evidence through 2026-09-20. https://marketontology.com/market-events/2026-09-20/electra-therapeutics-sets-terms-for-347m-nasdaq-ipo-under-ticker-etra-bce788

    CAPITAL
    Electra Therapeutics sets terms for $347M Nasdaq IPO under ticker ETRA
    Electra Therapeutics established pricing parameters for its upcoming Nasdaq listing, planning to raise up to $347 million across 21.7 million shares at $14-$16 each. The capital injection will fund the clinical development and pivotal registration trials of ipsoprubart, serving as a gauge for institutional ECM demand in clinical-stage biotherapeutics.
    ETRA
    Impact
    62
    SEP 20
    SIG
    85%
    ETRA
    Electra Therapeutics sets terms for $347M Nasdaq IPO under ticker ETRA
    Electra Therapeutics established pricing parameters for its upcoming Nasdaq listing, planning to raise up to $347 million across 21.7 million shares at $14-$16 each. The capital injection will fund the clinical development and pivotal registration trials of ipsoprubart, serving as a gauge for institutional ECM demand in clinical-stage biotherapeutics.
    → New clinical biotech issuance prices public equity liquidity conditions and institutional risk appetite for late-stage antibody pipelines.
    Impact
    Electra Therapeutics established pricing parameters for its upcoming Nasdaq listing, planning to raise up to $347 million across 21.7 million shares at $14-$16 each. The capital injection will fund the clinical development and pivotal registration trials of ipsoprubart, serving as a gauge for institutional ECM demand in clinical-stage biotherapeutics.
    Affected
    ETRA
    Transmission
    New clinical biotech issuance prices public equity liquidity conditions and institutional risk appetite for late-stage antibody pipelines.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ETRAprimary market pricing and clinical pipeline capital fundingWatch1-5dSource details terms of 21.7 million shares priced between $14-$16 on Nasdaq.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month